Coherus Biosciences | CHRS - Cash And Equivalent


Coherus Biosciences reported $88.88M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
Amgen USD 12.04B 2.91B Mar/2026
Baxter International USD 2.15B 133M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Fujifilm JPY 160.88B 906M Sep/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026
Zoetis USD 1.94B 369M Mar/2026